Evidence map›Paper›PMID 35087067›Full record

ArticleNPJ vaccines2022

Pre-existing antibodies directed against a tetramerizing domain enhance the immune response against artificially stabilized soluble tetrameric influenza neuraminidase.

João Paulo Portela Catani, Emma R Job, Tine Ysenbaert, Anouk Smet, Satyajit Ray, Lauren LaRue, Svetlana Stegalkina, Mario Barro, Thorsten U Vogel, Xavier Saelens

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

João Paulo Portela CataniVIB-UGent Center for Medical Biotechnology, VIB, B-9052, Ghent, Belgium.ORCID http://orcid.org/0000-0002-4866-3933
Emma R JobVIB-UGent Center for Medical Biotechnology, VIB, B-9052, Ghent, Belgium.ORCID http://orcid.org/0000-0001-7004-5763
Tine YsenbaertVIB-UGent Center for Medical Biotechnology, VIB, B-9052, Ghent, Belgium.
Anouk SmetVIB-UGent Center for Medical Biotechnology, VIB, B-9052, Ghent, Belgium.
Satyajit RaySanofi Pasteur, Research North America, Cambridge, MA, USA.
Lauren LaRueSanofi Pasteur, Research North America, Cambridge, MA, USA.
Svetlana StegalkinaSanofi Pasteur, Research North America, Cambridge, MA, USA.
Mario BarroSanofi Pasteur, Research North America, Cambridge, MA, USA.
Thorsten U VogelSanofi Pasteur, Research North America, Cambridge, MA, USA. Thorsten.Vogel@sanofi.com.ORCID http://orcid.org/0000-0002-0371-8048
Xavier SaelensVIB-UGent Center for Medical Biotechnology, VIB, B-9052, Ghent, Belgium. Xavier.Saelens@vib-ugent.be.ORCID http://orcid.org/0000-0002-3861-6965
Ghent University · BESanofi (United States) · USJanssen (Belgium) · BESanofi (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The neuraminidase (NA) is an abundant antigen at the surface of influenza virions. Recent studies have highlighted the immune-protective potential of NA against influenza and defined anti-NA antibodies as an independent correlate of protection. Even though NA head domain changes at a slightly slower pace than hemagglutinin (HA), NA is still subject to antigenic drift, and therefore an NA-based influenza vaccine antigen may have to be updated regularly and thus repeatedly administered. NA is a tetrameric type II membrane protein, which readily dissociates into dimers and monomers when expressed in a soluble form. By using a tetramerizing zipper, such as the tetrabrachion (TB) from Staphylothermus marinus, it is possible to stabilize soluble NA in its active tetrameric conformation, an imperative for the optimal induction of protective NA inhibitory antibodies. The impact of repetitive immunizations with TB-stabilized antigens on the immunogenicity of soluble TB-stabilized NA is unknown. We demonstrate that TB is immunogenic in mice. Interestingly, preexisting anti-TB antibodies enhance the anti-NA antibody response induced by immunization with TB-stabilized NA. This immune-enhancing effect was transferable by serum and operated independently of activating Fcγ receptors. We also demonstrate that priming with TB-stabilized NA antigens, enhances the NA inhibitory antibody responses against a heterosubtypic TB-stabilized NA. These findings have implications for the clinical development of oligomeric vaccine antigens that are stabilized by a heterologous oligomerizing domain.

Identifiers

PMID35087067
PMCPMC8795415
OpenAlexW4210515447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.